drugset
drugset / Trial / NCT01115751

A Study in Patients With Advanced or Metastatic Cancer

NCT01115751 ↗

Phase 1 Completed 80 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

Study JWAA is a multicenter, nonrandomized, open-label, dose-escalation Phase 1 study of oral LY2780301 in patients with advanced solid tumors.

Timeline

Start
2010-03
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject LY2780301 Unknown 100 mg Oral
Subject LY2780301 Unknown 200 mg Oral
Subject LY2780301 Unknown 300 mg Oral
Subject LY2780301 Unknown 400 mg Oral
Subject LY2780301 Unknown 500 mg Oral
Subject LY2780301 Unknown 600 mg Oral

Indications

metastatic neoplasm